IPHASE产品HGPRT基因突变试剂盒助力科研院所发表重要文章
近日，北京大学使用IPHASE品牌产品：HGPRT 基因突变试剂盒在《Science Advances》权威期刊上发表文章《Pt-seq unveils the genomic binding pattern of platinum-based drugs》，影响因子12.5！
【摘要】
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genomewide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatinDNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.
完整版文献可在【IPHASE】公众号后台留言【获取文章】
再次恭喜文献发表，以及对我司产品的认可，希望以上文献能帮助大家了解目前研究进展及我们的核心技术，欢迎各位新老客户联系我们咨询、提出意见，愿我们的努力成果与您的科研碰撞出不一样的火花！
【摘要】
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genomewide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatinDNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.
完整版文献可在【IPHASE】公众号后台留言【获取文章】
再次恭喜文献发表，以及对我司产品的认可，希望以上文献能帮助大家了解目前研究进展及我们的核心技术，欢迎各位新老客户联系我们咨询、提出意见，愿我们的努力成果与您的科研碰撞出不一样的火花！
